Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics:
Introduction (0:00) The Biology of Head and Neck Cancer (15:41) The Multidisciplinary Treatment of Head and Neck Cancer (18:14) Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03) Radiation Therapy and Chemotherapy Side Effects (41:02) The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50) Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46) Tolerability Considerations with Xevinapant (1:06:13) The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35) Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27) The Tolerability of Immune Checkpoint Inhibitors (1:24:09) NCPD information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Adam S Kibel, Dr Laurence Klotz and Dr Sandy Srinivas, moderated by Dr Elisabeth I Heath, including the following topics:
Introduction (0:00) Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Kibel (2:39) Side Effects and Other Practical Considerations with Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Klotz (27:04) Current and Future Approaches to Hormonal Therapy for Metastatic Prostate Cancer — Dr Aggarwal (51:07) New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Srinivas (1:13:53) Other Novel Therapies for Patients with Metastatic Prostate Cancer — Dr Heath (1:38:52) CME information and select publications

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics:
Follicular Lymphoma (0:00) Mantle Cell Lymphoma (30:29) Diffuse Large B-Cell Lymphoma (55:01) Hodgkin Lymphoma (1:12:25) CME information and select publications

Featuring a slide presentation and related discussion from Dr Elias Jabbour, including the following topics:
Clinical management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL); factors in the selection of initial induction  treatment (0:00) Primary and secondary endpoint outcomes from the Phase III PhALLCON trial comparing ponatinib to imatinib, each with reduced-intensity chemotherapy, as front-line treatment for Ph-positive ALL (5:22) Efficacy and tolerability of ponatinib in combination with blinatumomab for patients with newly diagnosed Ph-positive ALL (17:04) Ongoing research with novel agents and strategies for Ph-positive ALL (24:47) CME information and select publications

Featuring an interview with Dr Elias Jabbour, including the following topics:
Evolution of research and therapeutic options for acute lymphoblastic leukemia (ALL) (0:00) Clinical and biological characteristics of ALL and implications for prognosis and disease management (6:36) Case: A 48-year-old woman with newly diagnosed Philadelphia chromosome-positive (Ph-positive) ALL attains complete remission with ponatinib/blinatumomab (14:03) Tolerability and improved quality of life with the chemotherapy-free combination of ponatinib and blinatumomab (24:17) Case: A 38-year-old man with newly diagnosed Ph-positive ALL experiences a complete molecular response with induction hyper-CVAD and ponatinib (27:10) CME information and select publications

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics:
Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00) Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46) Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40) Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26) Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55) Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39) CME information and select publications